2024-11-05 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**1) Performance Comparison:**

Abbott Laboratories (ABT) is a multinational healthcare company that develops, manufactures, and markets a broad range of healthcare products, including pharmaceuticals, medical devices, nutritionals, and diagnostics.

**Cumulative Return:**

* ABT: 111.83%
* S&P 500 (VOO): 131.78%

**Return Difference:** -19.95%

**Relative Divergence:** 20.54 (meaning its performance is in the 20.54 percentile of its historical performance relative to S&P 500)

**Alpha & Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-----|------|
| 2015 | -0.5% | 22.3% | -0.9% | 1.1 |
| 2016 | -9.1% | 14.7% | -20.1% | 1.1 |
| 2017 | 39.5% | 5.9% | 20.8% | 0.9 |
| 2018 | 26.5% | 11.7% | 37.9% | 1.1 |
| 2019 | 32.1% | 10.6% | 1.0% | 1.1 |
| 2020 | 40.0% | 31.1% | 20.6% | 0.9 |
| 2021 | 53.9% | 16.7% | 12.0% | 0.5 |
| 2022 | -63.4% | 30.1% | -17.1% | 0.8 |
| 2023 | -4.5% | 20.7% | -39.9% | 0.6 |
| 2024 | 10.9% | 16.5% | -24.3% | 0.2 |

**Analysis:** ABT has shown a relatively stable beta, suggesting its performance is moderately correlated with the overall market. The alpha has fluctuated significantly, indicating periods of both outperformance and underperformance compared to the benchmark.

**2) Recent Price Movement:**

* Closing price: 118.6 (Last market: 117.93)
* 5-day moving average: 114.78
* 20-day moving average: 115.94
* 60-day moving average: 114.15

**Analysis:** The stock price is trading above its 5-day, 20-day and 60-day moving averages, suggesting a potential short-term upward trend.

**3) Technical Indicators:**

* RSI: 53.43
* PPO: -0.14
* Recent (20-day) Relative Divergence: 8.96 (+) - short-term upward trend.
* Expected Return: 0.0% - This is the estimated long-term (2+ years) expected return relative to S&P 500, assuming consistent investment.

**Analysis:** The RSI indicates a moderately bullish sentiment. The PPO suggests a slightly bearish outlook. The positive relative divergence highlights the short-term upward trend, while the expected return suggests potential for long-term growth, though it may not significantly outperform the S&P 500.

**4) Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-31 | 0.94 | 10.63 B$ |
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2024-10-31 | 0.82 | 10.14 B$ |

**Analysis:** ABT has consistently exceeded revenue expectations in recent quarters. The most recent earnings report showed EPS of $0.94, exceeding analysts' estimates. This suggests a positive growth trajectory, but it's important to consider macro-economic factors that might impact the company's future performance.

**5) Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $10.63B | 55.83% |
| 2024-06-30 | $10.38B | 55.64% |
| 2024-03-31 | $9.96B | 55.21% |
| 2023-12-31 | $10.24B | 55.51% |
| 2023-09-30 | $10.14B | 54.60% |

**Analysis:** ABT demonstrates consistent profitability with a high and stable profit margin, reflecting its strong market position and efficient operations.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $39.80B | 4.14% |
| 2024-06-30 | $39.32B | 3.31% |
| 2024-03-31 | $38.81B | 3.16% |
| 2023-12-31 | $38.60B | 4.13% |
| 2023-09-30 | $37.48B | 3.83% |

**Analysis:**  ABT maintains a strong capital position with consistent equity growth.  The ROE shows a slight downward trend but remains healthy, indicating efficient use of shareholder capital. 

**6) News and Recent Issues:**

**Recent Earnings News:**

* On November 1st, 2024, ABT reported its Q3 2024 earnings, beating analysts' expectations with EPS of $0.94 and revenue of $10.63 Billion. 

**Recent Market Outlook:**

* **Finbold** reported that ABT is expected to maintain its strong growth trajectory in the coming quarters, driven by its robust product portfolio and global market presence. 
* **Analysts** are generally optimistic about ABT's long-term outlook, citing its strong brand recognition, established distribution network, and continuous investment in research and development.

**7) Summary:**

ABT is a well-established company with a strong track record of consistent profitability and a diversified product portfolio. It has a relatively stable performance compared to the broader market, but its recent earnings and positive market outlook suggest a potential for long-term growth. The stock's technical indicators suggest a short-term upward trend, but the expected return does not indicate significant outperformance over the S&P 500 in the long term. 

**Note:** This analysis is based on the provided information and should not be considered investment advice. Before making any investment decisions, it is essential to conduct your own thorough research and consult with a financial advisor. 
